# Animal models to study zoonotic

# infections

### Joaquim Segalés

joaquim.segales@irta.cat

🄰 @QuimSegales







Biosafety level 3 animal and laboratory facilities

Campus UAB (Universitat Autònoma de Barcelona, Spain)



## General design of IRTA-CReSA – "Sandwich system"



# **Technical details**

- Gradient of negative pressure
- Entrance of people
- Protecting people (Personal Protective Equipments)
- Entrance of animals and other materials
- Boxes for animals
- Residue treament
- Air filtration
- ... and many more...









# Animal facilities at IRTA-CReSA

Cages for small mammals





Climatic chamber for entomology













Boxes for livestock

and wildlife



# Animal species we have been working with

- Pig
- Wild boar
- Sheep
- Cattle
- Goat
- Horse (pony)
- Dromedary camel
- Alpaca
- Llama
- Deer
- Chamois
- Ferret

- Golden Syrian hamster
- Mice (different types)
- Rat
- Voles
- Chicken
- Duck
- Turkey
- Pigeon
- Quail
- Falcon
- Partridge
- Goose



Occasionally, plant BSL3 pathogens

# ... But we are here today to talk about animal models and zoonotic diseases...



## Translational vaccinology/medicinal products

- Interdisciplinary approach built on basic research advances used to develop new vaccine/medicinal products:
  - Study of biological *in vitro* processes



Vaccinology is based on the immune response of humans and animals as well as its measurement, which limits the scope of models to work with

#### Induced animal models



https://www.sciencedirect.com/science/article/pii/B9780128163528000084



Grant Agreement number: 280873 Project acronym: ADITEC Project title: Advanced Immunization Technologies

# **Usefulness of animal models**

- The development of pharmaceutical and vaccine products for humans has a number of limitations: some efficacy studies are not ethical or feasible!!
- The advantage for developing animal vaccines is that you can do the research in the target species

**Essential!!!** (preclinical development for human vaccines, and preclinical and clinical development for animal vaccines)

## **Animal models and ethics**





https://healthculturesociety2015.wikispaces.com

## "The Animal Rule" (FDA, 2015)

- "Product Development Under the Animal Rule Guidance for Industry"
- FDA "may grant marketing approval based on <u>adequate and well-</u> <u>controlled animal efficacy studies</u> when the results of those studies establish that <u>the drug is reasonably likely to produce clinical benefit in</u> <u>humans</u>".

# Usefulness of animal models for the development of products for humans

• "Mice lie and monkeys exaggerate..."



http://www.keyword-suggestions.com

Sentence attributed toDr. David B. Weiner, University of Pennsylvania, USA



### Usefulness of animal models for the development of products for humans



http://www.mitearrest.com

- Easy management
- Quick time of generation
- Genetically modifiable
- Availability of laboratory reagents

How representative of human diseases?; possibility of "humanization", and "knockout" and transgenic mice



https://en.wikipedia.org/wiki/Rhesus\_macaque

• More similar to human diseases

High legal regulations and animal welfare and ethic considerations; difficult to work in environments BSL3 and BSL4

### Usefulness of animal models for the development of products for humans

- Models with **large animals** may represent **better models** for some human diseases (Levast et al., 2013; Seok et al., 2013)
  - Similarity with human diseases
  - Access to different tissue compartments
  - Similarity with the immune response
  - Multiple "readouts" availability for vaccine safety and efficacy

Gerdts et al., 2015

# Usefulness of animal models for the development of products for humans

- Some of the best animal models for certain human diseases are not easy to be expected:
  - Human influenza viruses  $\Rightarrow$  **ferret**
  - Human rotaviruses  $\Rightarrow$  **gnotobiotic pig**
  - Hespes simplex virus  $1 \Rightarrow$  Aujeszky's disease virus in **pigs**
- Pigs, ruminants and horeses may represent good animal models for human diseases

### The pig as a model for infectious diseases

#### Pig models for human infectious diseases

| Pathogen               | Comments   |  |
|------------------------|--|--|
| Influenza virus        | Various ages (Influenza C and Influenza A subtypes H1N1, |  |
|                        | H1N2, H2N1, H3N1, H3N2 and H2N3)                         |  |
| Rotavirus              | Neonatal gnotobiotic pigs                                |  |
| Norovirus              | Neonatal gnotobiotic pigs                                |  |
| Herpes simplex 1       | Host-virus interaction                                   |  |
| Nipah virus            | Young pigs   |  |
| Bordetella pertussis   | Neonatal pigs  |  |
| Escherichia coli       | Various ages, including neonatal pigs                    |  |
| Salmonella spp.        | Neonatal gnotobiotic pigs                                |  |
| Shigella spp.          | Neonatal gnotobiotic pigs                                |  |
| Clostridium spp.       | Neonatal gnotobiotic pigs                                |  |
| Brucella (suis)        | Various ages   |  |
| Staphylococcus aureus  | Young pigs   |  |
| Pseudomona aeruginosa  | Various ages   |  |
| Helicobacter pylori    | Neonatal gnotobiotic pigs                                |  |
| Acanthamoeba keratitis | Adult Yucatan micropigs                                  |  |
| Chlamydia trachomantis | Adult female (genital model)                             |  |

### **Ruminants as a model for infectious diseases**

Sheep and cattle models for human infectious diseases

| Pathogen                    | Sheep                     | Cattle                        |
|-----------------------------|---------------------------|-------------------------------|
| Parainfluenza virus         | Neonatal                  | Various ages, including       |
|                             |                           | neonatal calves               |
| Papilloma virus             | -                         | Adult                         |
| Mycobacterium tuberculosis  | -                         | Various ages, including       |
|                             |                           | neonatal calves               |
| Escherichia coli            | Various ages              | Various ages, including       |
|                             |                           | neonatal calves               |
| Schistosomiasis             |                           | Various ages                  |
| Brucellosis                 | Various ages              | Various ages                  |
| Respiratory syncytial virus | Various ages, including   | Various ages, including       |
|                             | neonatal lamb (models for | neonatal calves (bovine virus |
|                             | human and bovine viruses) | only as a model)              |
| Rotavirus                   | -                         | Neonatal gnotobiotic calves   |
| Salmonella spp.             | Various ages              | -                             |

### **Animal models and zoonoses**

- Livestock species may be excellent models to study some zoonotic diseases, since the vaccines are tested in the own animal host
- Sometimes the animal host is able to display a <u>clinical</u> <u>disease very similar to that of humans</u>, but in a number of cases, probably as a result of <u>host-pathogen co-</u> <u>evolution</u>, hosts are just experiencing subclinical infections and act as <u>reservoirs</u>

## **Building up an animal model**

- Do we have the right animal species to work with? ANIMAL SPECIES
  SELECTION
- Do we have the right health status of the animal species selected? **CLINICAL AND LABORATORY DIAGNOSIS/MONITORING**
- Do we have the right facilities/animal caretakers to work on the animal model? WHICH TYPE OF PATHOGEN SHOULD WE WORK WITH?
  BSL2? BSL3? OTHER?

### A couple of examples... zoonòtic coronaviruses

#### **MERS-CoV**

#### SARS-CoV-2



#### El misterioso origen del virus responsable del covid-19



# Working with zoonotic coronaviruses at IRTA-CReSA

- Working with MERS-CoV animal models since 2014
- Working with SARS-CoV-2 animal models since 2020



# BSL3 laboratory facilities: PPE for MERS-CoV or SARS-CoV-2

- FPP3 mask (North)
- Sundström ventilated (positive pressure) overhead protection SR530 with filter SR510 and ventilator SR500
- Two pairs of gloves
- Second cover for working on box or laboratory (Tyvek<sup>®</sup>).







# Biosafety measures for MERS-CoV or SARS-CoV-2 in animal box





이 있고, 종

한 접촉물 빈

VO BING

 One cannot "white a sevenerate travelse white developed travel and antih reconstruct lowes white fractional the contents in a time Forver OR sympositions of neighborary timeses ANO closs With a confirmed MERS case while the case was till. \*Audate Pentitial: \*Cadate Pentitial: \*Cadate Contents \*\*Case contents \*\*Case and the case of the case of the case of the content of the case of the case

CARLES / 서울대학교병원

# MERS-CoV: vaccination of camelids as a first option to control the transmission of the virus to humans





#### An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

Bart L. Haagmans,<sup>1\*</sup> Judith M. A. van den Brand,<sup>1</sup> V. Stalin Raj,<sup>1</sup> Asisa Volz,<sup>2</sup> Peter Wohlsein,<sup>3</sup> Saskia L. Smits,<sup>1</sup> Debby Schipper,<sup>1</sup> Theo M. Bestebroer,<sup>1</sup> Nisreen Okba,<sup>1</sup> Robert Fux,<sup>2</sup> Albert Bensaid,<sup>4</sup> David Solanes Foz,<sup>4</sup> Thijs Kuiken,<sup>1</sup> Wolfgang Baumgärtner,<sup>3</sup> Joaquim Segalés,<sup>5,6</sup> Gerd Sutter,<sup>2\*</sup> Albert D. M. E. Osterhaus<sup>1,7,8\*</sup>



Mild clinical signs in camelids

Detection of MERS-CoV RNA and infectious virus in nasal swabs

#### Histopathology and expression of viral antigen and

#### viral RNA in nasal respiratory epithelium



# Not easy to work with dromedary camels...





¥ f ⊟

#### IN THE LAB

Think your job is hard? Try squirting a vaccine up a camel's nostrils





L'ive Leak



## **Potential surrogates for camels?**



Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein

Jordi Rodon, Nisreen M. A. Okba, Nigeer Te, Brenda van Dieren, Berend-Jan Bosch, Albert Bensaid, Joaquim Segalés, Bart L. Haagmans & Júlia Vergara-Alert





Type I and III IFNs produced by the nasal epithelia and dimmed inflammation are features of alpacas resolving MERS-CoV infection

Nigeer Te<sup>1°</sup>, Jordi Rodon<sup>1°</sup>, Maria Ballester<sup>2</sup>, Mónica Pérez<sup>1</sup>, Lola Pailler-García<sup>1</sup>, Joaquim Segalés<sup>3,4</sup>, Júlia Vergara-Alert<sup>1</sup>\*, Albert Bensaid<sup>1</sup>

#### **PLOS PATHOGENS**





NTINE

QUARANTI

# SARS-CoV-2: Vaccination of people; preclinical studies in animals



# Experimental infections in animals: which ones have been tested?



*Cynomolgus macaque* hACE2 transgenic and other NHP mice

Ferret

Golden Syrian hamster

Egyptian fruit bat Racoon dog

Bank vole

Rabbit



Bao et al., 2020; Chan et al., 2020; Hallmann et al., 2020; Richard et al., 2020; Rockx et al., 2020; Shi et al., 2020; Schlottau et al., 2020, Ulrich et al., 2020; Freuling et al., 2020; Mykytyn et al., 2020; Xu et al., 2020; FLI 2021; Palmer et al., 2021

# Experimental infections in animals: which ones are susceptible?



*Cynomolgus macaque* and other NHP hACE2 transgenic mice Ferret

Golden Syrian hamster Egyptian fruit bat

Racoon dog

Bank vole

Rabbit



Bao et al., 2020; Chan et al., 2020; Hallmann et al., 2020; Richard et al., 2020; Rockx et al., 2020; Shi et al., 2020; Schlottau et al., 2020, Ulrich et al., 2020; Freuling et al., 2020; Mykytyn et al., 2020; Xu et al., 2020; FLI 2021, Palmer et al., 2021

#### nature

#### Review

### **Animal models for COVID-19**

https://doi.org/10.1038/s41586-020-2787-6

Received: 22 June 2020

Accepted: 15 September 2020

Published online: 23 September 2020

Check for updates

César Muñoz-Fontela<sup>1,2</sup>, William E. Dowling<sup>3</sup>, Simon G. P. Funnell<sup>4</sup>, Pierre-S. Gsell<sup>5</sup>, A. Ximena Riveros-Balta<sup>5</sup>, Randy A. Albrecht<sup>6</sup>, Hanne Andersen<sup>7</sup>, Ralph S. Baric<sup>8</sup>, Miles W. Carroll<sup>4</sup>, Marco Cavaleri<sup>9</sup>, Chuan Qin<sup>10</sup>, Ian Crozier<sup>11</sup>, Kai Dallmeier<sup>12</sup>, Leon de Waal<sup>13</sup>, Emmie de Wit<sup>14</sup>, Leen Delang<sup>12</sup>, Erik Dohm<sup>15</sup>, W. Paul Duprex<sup>16</sup>, Darryl Falzarano<sup>17</sup>, Courtney L. Finch<sup>18</sup>, Matthew B. Frieman<sup>19</sup>, Barney S. Graham<sup>20</sup>, Lisa E. Gralinski<sup>8</sup>, Kate Guilfoyle<sup>13</sup>, Bart L. Haagmans<sup>21</sup>, Geraldine A. Hamilton<sup>22</sup>, Amy L. Hartman<sup>16</sup>, Sander Herfst<sup>21</sup>, Suzanne J. F. Kaptein<sup>12</sup>, William B. Klimstra<sup>23</sup>, Ivana Knezevic<sup>5</sup>, Philip R. Krause<sup>24</sup>, Jens H. Kuhn<sup>18</sup>, Roger Le Grand<sup>25</sup>, Mark G. Lewis<sup>7</sup>, Wen-Chun Liu<sup>6</sup>, Pauline Maisonnasse<sup>25</sup>, Anita K. McElroy<sup>26</sup>, Vincent Munster<sup>14</sup>, Nadia Oreshkova<sup>27</sup>, Angela L. Rasmussen<sup>28</sup>, Joana Rocha-Pereira<sup>12</sup>, Barry Rockx<sup>21</sup>, Estefanía Rodríguez<sup>1,2</sup>, Thomas F. Rogers<sup>29</sup>, Francisco J. Salguero<sup>4</sup>, Michael Schotsaert<sup>6</sup>, Koert J. Stittelaar<sup>13</sup>, Hendrik Jan Thibaut<sup>12</sup>, Chien-Te Tseng<sup>30</sup>, Júlia Vergara-Alert<sup>31</sup>, Martin Beer<sup>32</sup>, Trevor Brasel<sup>30</sup>, Jasper F. W. Chan<sup>33</sup>, Adolfo García-Sastre<sup>6</sup>, Johan Neyts<sup>12</sup>, Stanley Perlman<sup>34</sup>, Douglas S. Reed<sup>23</sup>, Juergen A. Richt<sup>35</sup>, Chad J. Roy<sup>36</sup>, Joaquim Segalés<sup>31,37</sup>, Seshadri S. Vasan<sup>38,39</sup>, Ana María Henao-Restrepo<sup>5</sup> & Dan H. Barouch<sup>40</sup>

#### **PLOS PATHOGENS**

REVIEW

# Advances and gaps in SARS-CoV-2 infection models

César Muñoz-Fontela<sup>1,2</sup>, Lina Widerspick<sup>1,2</sup>, Randy A. Albrecht<sup>3</sup>, Martin Beer<sup>4</sup>, Miles W. Carroll<sup>5,6</sup>, Emmie de Wit<sup>7</sup>, Michael S. Diamond<sup>8</sup>, William E. Dowling<sup>9</sup>, Simon G. P. Funnell<sup>5</sup>, Adolfo García-Sastre<sup>3</sup>, Nora M. Gerhards<sup>10</sup>, Rineke de Jong<sup>10</sup>, Vincent J. Munster<sup>7</sup>, Johan Neyts<sup>11</sup>, Stanley Perlman<sup>12</sup>, Douglas S. Reed<sup>13</sup>, Juergen A. Richt<sup>14</sup>, Ximena Riveros-Balta<sup>15</sup>, Chad J. Roy<sup>16</sup>, Francisco J. Salguero<sup>5</sup>, Michael Schotsaert<sup>3</sup>, Lauren M. Schwartz<sup>15</sup>, Robert A. Seder<sup>17</sup>, Joaquim Segalés<sup>18</sup>, Seshadri S. Vasan<sup>19</sup>, Ana María Henao-Restrepo<sup>15</sup>, Dan H. Barouch<sup>20</sup>\*

### **Use of different animal models**



K18-hACE2 transgenic mice

**Golden Syrian hamster** 

### **Golden Syrian** hamster model



а



7 dpi

Brustolin et al., 2021

### hACE2 transgenic mice model



Vidal et al., 2021



# **General thoughts**

- Permanent need to develop pharmaceutical and vaccine products
- Need to develop new platforms to design and produce products
  Necesidad de desarrollo de nuevos modelos animales
- Need to expand the espectre of preclinical possibilities:
  - To reduce the number of animals in the experiment
  - Use of alternative methods to animal experimentation
  - How to reproduce the biological variability

# Alternative methods for animal experimentation

https://tisserandinstitute.org/sars-cov-2-essential-oils-in-silico-studies/

- *In silico* methods or computer models
- In vitro cell-based models
  - Immortalized cell lines
  - Primary cells
- Three-dimensional (3D) models
  - Organoids
  - Organ-on-a-chip









https://kosheeka.com/how-do-primary-cells-differ-from-continuous-cell-lines/



https://wyss.harvard.edu/technology/ human-organs-on-chips/

# PERSPECTIVES

# Reproducibility of animal research in light of biological variation

Bernhard Voelkl, Naomi S. Altman, Anders Forsman, Wolfgang Forstmeier, Jessica Gurevitch, Ivana Jaric, Natasha A. Karp, Martien J. Kas, Holger Schielzeth, Tom Van de Casteele, and Hanno Würbel

"In contrast to the current gold standard of rigorous standardization in experimental animal research, we recommend the use of systematic heterogenization of study samples and conditions by actively incorporating biological variation into study design through diversifying study samples and conditions."



#### OIE Animal Health @OIEAnimalHealth · 54m

Preventing future pandemics will likely cost between \$18-\$27 billion/year over 10 years. That may seem like a lot, but it's less than 1% of the cost of the current pandemic & avoids the additional suffering & disruption.

It's time to invest in pandemic prevention! #OneHealth



...



# Many thanks for your attention!